L1-Specific Protection from Tumor Challenge Elicited by HPV16 Virus-like Particles-Reference-Cited by-同舟云学术

L1-Specific Protection from Tumor Challenge Elicited by HPV16 Virus-like Particles

Published:1998-10 Issue:2 Volume:250 Page:371-376
ISSN:0042-6822
Container-title:Virology
language:en
Short-container-title:Virology

Author:

De Bruijn Marloes L.H.,Greenstone Heather L.,Vermeulen Hans,Melief Cornelis J.M.,Lowy Douglas R.,Schiller John T.,Kast W.Martin

Publisher

Elsevier BV

Subject

Virology

Reference23 articles.

1. Structural and serological similarity of MHC-linked LMP and proteasome (multicatalytic proteinases) complexes;Brown;Nature,1991

2. Surface conformational and linear epitopes on HPV-16 and HPV-18 L1 virus-like particles as defined by monoclonal antibodies;Christensen;Virology,1996

3. Characterization of the murine T cell surface molecule designated L3T4, identified by monoclonal antibody GK1.5: similarity of L3T4 to the human Leu-3/T4 molecule;Dialynas;J. Immunol.,1983

4. Cell mediated immunity induced in mice by HPV16 L1 virus-like particles;Dupuy;Micro. Pathol.,1997

5. Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells;Feltkamp;Eur. J. Immunol.,1993

Cited by 64 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Brucella abortus RB51 lipopolysaccharide influence as an adjuvant on the therapeutic efficacy of HPV16 L1 and HPV16 E7 DNA vaccines;IRAN J BASIC MED SCI;2021

2. Combined prophylactic and therapeutic immune responses against human papillomaviruses induced by a thioredoxin-based L2-E7 nanoparticle vaccine;PLOS Pathogens;2020-09-04

3. DRH1 – a novel blood-based HPV tumour marker;EBioMedicine;2020-06

4. Different types of adjuvants in prophylactic and therapeutic human papillomavirus vaccines in laboratory animals: a systematic review;Archives of Virology;2019-12-04

5. Explanations for the high potency of HPV prophylactic vaccines;Vaccine;2018-08